Regorafenib Approved for Hepatocellular Carcinoma

Share this content:
Regorafenib Approved for Hepatocellular Carcinoma
Regorafenib Approved for Hepatocellular Carcinoma

THURSDAY, April 27, 2017 (HealthDay News) -- U.S. Food and Drug Administration approval of the kinase inhibitor regorafenib (Stivarga) has been expanded to include hepatocellular carcinoma, the agency said Thursday in a news release.

Regorafenib is the first drug approved to treat hepatocellular carcinoma in nearly a decade, the FDA said. Regorafenib is already FDA-approved to treat colorectal cancer and gastrointestinal stromal tumors, the agency said. The drug was approved for hepatocellular carcinoma patients treated previously with sorafenib.

Regorafenib's effectiveness for treating hepatocellular carcinoma was evaluated in a randomized trial of 573 people whose tumors had progressed despite treatment with sorafenib. The most common adverse events included gastrointestinal and abdominal pain, skin reactions, fatigue, diarrhea, loss of appetite, hypertension, and infection. More serious adverse events included hepatotoxicity, hemorrhage, gastrointestinal perforation or fistula, and cardiac ischemia and infarction.

Women who are pregnant or breastfeeding should not take regorafenib, the FDA said. And patients of both genders of child-bearing age who take the drug should use contraception, the agency added.

Approval of Stivarga was granted to Bayer HealthCare Pharmaceuticals, based in Whippany, New Jersey.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »